stella
beta
Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors — Stella
Recruiting
Back to Solid Tumor trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
Children's National Hospital, Washington D.C., District of Columbia
View full record on ClinicalTrials.gov